RT001-014 is a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects with Amyotrophic Lateral Sclerosis
Forty subjects at 4 EU sites will undergo baseline examination, and then be randomized 1:1 to receive either RT001 or placebo. Repeat visits will occur every 2 months. The final visit will be at 6 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
43
University of Tartu
Tartu, Estonia
Riga Stradins Universtiy
Riga, Latvia
UMC Utrecht
Utrecht, Netherlands
Karolinska
Stockholm, Sweden
Change from baseline in the revised ALS Functional Rating Score (ALSFRS-R) at 24 weeks
Change from baseline in ALSFRS-R will be compared for the RT001 treated group vs placebo
Time frame: 24 weeks
Composite of Death or a Specified State of Disease Progression
Change from baseline in the composite endpoint will be compared for the RT001 treated group vs placebo
Time frame: 24 weeks
Change from Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40)
Change from baseline in ALSAQ40 will be compared for the RT001 treated group vs placebo
Time frame: 24 weeks
Change from baseline in SVC
Change from baseline in SVC will be compared for the RT001 treated group vs placebo
Time frame: 24 weeks
Frequency, severity and relationship to study drug of AEs and SAEs
Frequency, severity and relationship to study drug of AEs and SAEs will be compared for the RT001 treated group vs placebo
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.